We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%. Meanwhile, the Dow experienced a drop of 0.99%, and the technology-dominated Nasdaq saw a decrease of 2.61%.
Prior to today's trading, shares of the drugmaker had gained 10.39% over the past month. This has outpaced the Medical sector's gain of 0.26% and the S&P 500's loss of 3.48% in that time.
Market participants will be closely following the financial results of Eli Lilly in its upcoming release. The company is expected to report EPS of $4.60, up 78.29% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $12.72 billion, up 45.03% from the year-ago period.
LLY's full-year Zacks Consensus Estimates are calling for earnings of $23.47 per share and revenue of $59.92 billion. These results would represent year-over-year changes of +80.68% and +33.02%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.48% lower. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Eli Lilly is at present trading with a Forward P/E ratio of 39.62. This represents a premium compared to its industry's average Forward P/E of 14.5.
It is also worth noting that LLY currently has a PEG ratio of 1.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. LLY's industry had an average PEG ratio of 1.44 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Eli Lilly (LLY) Dips More Than Broader Market: What You Should Know
Eli Lilly (LLY - Free Report) ended the recent trading session at $912.76, demonstrating a -1.82% swing from the preceding day's closing price. The stock's performance was behind the S&P 500's daily loss of 1.78%. Meanwhile, the Dow experienced a drop of 0.99%, and the technology-dominated Nasdaq saw a decrease of 2.61%.
Prior to today's trading, shares of the drugmaker had gained 10.39% over the past month. This has outpaced the Medical sector's gain of 0.26% and the S&P 500's loss of 3.48% in that time.
Market participants will be closely following the financial results of Eli Lilly in its upcoming release. The company is expected to report EPS of $4.60, up 78.29% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $12.72 billion, up 45.03% from the year-ago period.
LLY's full-year Zacks Consensus Estimates are calling for earnings of $23.47 per share and revenue of $59.92 billion. These results would represent year-over-year changes of +80.68% and +33.02%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These recent revisions tend to reflect the evolving nature of short-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's business performance and profit potential.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 1.48% lower. At present, Eli Lilly boasts a Zacks Rank of #3 (Hold).
In the context of valuation, Eli Lilly is at present trading with a Forward P/E ratio of 39.62. This represents a premium compared to its industry's average Forward P/E of 14.5.
It is also worth noting that LLY currently has a PEG ratio of 1.49. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. LLY's industry had an average PEG ratio of 1.44 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This group has a Zacks Industry Rank of 146, putting it in the bottom 42% of all 250+ industries.
The strength of our individual industry groups is measured by the Zacks Industry Rank, which is calculated based on the average Zacks Rank of the individual stocks within these groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.